Biocon receives DCGI approval for anti-psoriasis drug
Biocon is now permitted to market Itolizumab, a drug used in the treatment of psoriasis.
New Delhi, January 8, 2013: The biotechnology drug firm, Biocon, today said that the company has received approval from the drug controller, DCGI, to market its product Itolizumab, a drug used in the treatment of psoriasis.
The company said in a statement that it has received market authorisation from the Drug Controller General of India (DCGI) for its novel biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque psoriasis.
The company further said that the approval paves way for the launch of the drug later in 2013 in the country. "We are very excited to receive this marketing authorisation for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India,” said Ms Kiran Mazumdar Shaw, CMD, Biocon.
The company also said that it plans to file a US IND (Investigational New Drug) shortly to be able to embark on a global clinical development plan.
The global Psoriasis market size is expected to cross US$ 8 billion by 2016.